Spyre Therapeutics earnings jolt investor focus Spyre Therapeutics (SYRE) has moved into the spotlight after third quarter results showed a net loss of US$96.12 million, compared with US$11.18 million...
Source LinkSpyre Therapeutics earnings jolt investor focus Spyre Therapeutics (SYRE) has moved into the spotlight after third quarter results showed a net loss of US$96.12 million, compared with US$11.18 million...
Source Link
Comments